Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the 'address' sequence

Journal of Medicinal Chemistry

Volumn 40, Issue 8, 1997, Pages 1211-1218

  Arttamangkul, Seksiri ^a   Ishmael, Jane E ^a   Murray, Thomas F ^a   Grandy, David K ^b   DeLander, Gary E ^a   Kieffer, Brigitte L ^c   Aldrich, Jane V ^a,d  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Ecl Sup de Biotech de Strasbourg   (France)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN A; DYNORPHIN A DERIVATIVE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPIATE RECEPTOR; RECEPTOR SUBTYPE; SIGMA OPIATE RECEPTOR;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DISULFIDE BOND; GUINEA PIG; ILEUM; LIGAND BINDING; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR AFFINITY;

ANIMALS; CIRCULAR DICHROISM; COS CELLS; DYNORPHINS; NARCOTICS; PROTEIN CONFORMATION; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031003877     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960753p     Document Type: Article

References (33)

1. Part 1: Arttamangkul, S.; Murray, T. F.; DeLander, G. E.; Aldrich, J. V. Synthesis and Opioid Activity of Conformationally Constrained Dynorphin A Analogues. 1. Conformational Constraint in the "Message" Sequence. J. Med. Chem. 1995, 38, 2410-2417.
2. Simon, E. J.; Hiller, J. M. Opioid Peptides and Opioid Receptors. In Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, 5th ed.; Siegel, G. J., et al., Eds.; Raven Press, Ltd.: New York, 1994; pp 321-339.
3. Hruby, V. J.; Al-Obeidi, F.; Kazmierski, W. Emerging Approaches in the Molecular Design of Receptor-Selective Peptide Ligands: Conformational, Topographical and Dynamic Considerations. Biochem. J. 1990, 268, 249-262.
4. Chavkin, C.; James, I. F.; Goldstein, A. Dynorphin is a Specific Endogenous Ligand of the κ Opioid Receptor. Science 1982, 215, 413-415.
5. Chavkin, C.; Goldstein, A. Specific Receptor for the Opioid Peptide Dynorphin: Structure-Activity Relationships. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 6543-6547.
6. Turcotte, A.; LaLonde, J.-M.; St-Pierre, S.; LeMaire, S. Dynorphin-(1-13) I. Structure-Function Relationships of Ala-Containing Analogs. Int. J. Pept. Protein Res. 1984, 23, 361-367.
7. Snyder, K. R.; Story, S. C.; Heidt, M. E.; Murray, T. F.; DeLander, G. E.; Aldrich, J. V. Effect of Modification of the Basic Residues of Dynorphin A-(1-13) Amide on κ Opioid Receptor Selectivity and Opioid Activity. J. Med. Chem. 1992, 35, 4330-4333.
8. Story, S. C.; Murray, T. F.; DeLander, G. E.; Aldrich, J. V. Synthesis and Opioid Activity of 2-Substituted Dynorphin A-(1-13) Amide Analogues. Int. J. Pept. Protein Res. 1992, 40, 89-96.
9. Kawasaki, A. M.; Knapp, R. J.; Walton, W. S.; Zalewska, T.; Yamamura, H. I.; Porreca, F.; Burks, T. M.; Hruby, V. J. Syntheses, Opioid Binding Affinities, and Potencies of Dynorphin A Analogues Substituted in Positions 1,6,7,8 and 10. Int. J. Pept. Protein Res. 1993, 42, 411-419.
10. Goldstein, A.; Tachibana, J. S.; Lowney, L. I.; Hunkapiller, M. Dynorphin-(1-13), an Extraordinarily Potent Opioid Peptide. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 6666-6670.
11. Renugopalakrishnan, V.; Paraka, R. S.; Bhargava, H. N. Conformational Features of Opioid Peptides: Ligand Receptor Interactions. In Opioid Peptides, Biochemistry and Applied Physioligy; Székely, J. I., Ramabadran, K., Eds.; CRC Press: Boston, 1990; Vol. IV, pp 53-114.
12. 5]Enkephalin. Life Sci. 1982, 31, 1777-1780.
13. Shearman, G. T.; Schulz, R.; Schiller, P. W.; Herz, A. Generalization Tests with Intraventricularly Applied Pro-enkephalin B Derived Peptides in Rats Trained to Discriminate the Opioid Kappa Receptor Agonist Ethylketocyclazocine. Psychopharmacology 1985, 85, 440-443.
14. Kawasaki, A. M.; Knapp, R. J.; Kramer, T. H.; Wire, W. S.; Vasquez, O. S.; Yamamura, H. I.; Burks, T. F.; Hruby, V. J. Design and Synthesis of Highly Potent and Selective Cyclic Dynorphin A Analogs. J. Med. Chem. 1990, 33, 1874-1879.
15. Kawasaki, A. M.; Knapp, R. J.; Kramer, T. H.; Walton, A.; Wire, W. S.; Hashimoto, S.; Yamamura, H. I.; Porreca, F.; Burks, T. F.; Hruby, V. J. Design and Synthesis of Highly Potent and Selective Cyclic Dynorphin A Analogs. 2. New Analogs. J. Med. Chem. 1993, 36, 750-757.
16. Meyer, J.-P.; Collins, N.; Lung, F.-D.; Davis, P.; Zalewska, T.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. Design, Synthesis, and Biological Properties of Highly Potent Cyclic Dynorphin A Analogues. Analogues Cyclized between Positions 5 and 11. J. Med. Chem. 1994, 37, 3910-3917.
17. Schiller, P. W.; Nguyen, T. M.-D.; Lemieux, C. Synthesis and Opioid Activity Profile of Cyclic Dynorphin Analogs. Tetrahedron 1988, 44, 733-743.
18. Schwyzer, R. Molecular Mechanism of Opioid Receptor Selection. Biochemistry 1986, 25, 6335-6342.
19. Schwyzer, R. Estimated Conformation, Orientation and Accumulation of Dynorphin A-(1-13)-tridecapeptide on the Surface of the Neutral Lipid Membranes. Biochemistry 1986, 25, 4281-4286.
20. Kallick, D. Conformation of Dynorphin A(1-17) Bound to Dodecylphosphocholine. J. Am. Chem. Soc. 1993, 115, 9317-9318.
21. Weiner, P. K.; Kollman, P. A. AMBER: Assisted Model Building with Energy Refinement. A General Program for Modeling Molecules and Their Interactions. J. Comput. Chem. 1981, 2, 287-303.
22. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S., Jr.; Weiner, P. K. A New Force Field for Molecular Mechanical Simulation of Nucleic Acids and Proteins. J. Am. Chem. Soc. 1984, 106, 765-784.
23. Weiner, S. J.; Kollman, P. A. An All Atom Force Field for Simulations of Proteins and Nucleic Acids. J. Comput. Chem. 1986, 7, 230-252.
24. King, D. S.; Fields, C. G.; Fields, G. B. A Cleavage Method Which Minimizes Side Reactions Following Fmoc Solid Phase Peptide Synthesis. Int. J. Pept. Protein Res. 1990, 36, 255-266.
25. 2. J. Med. Chem. 1995, 38, 585-586.
26. Hay, R. W.; Morris, P. J. Proton Ionisation Constants and Kinetics of Base Hydrolysis of Some α-Amino-acid Esters in Aqueous Solution. Part III. Hydrolysis and Intramolecular Aminolysis of αω-Diamino-acid Methyl Esters. J. Chem. Soc., Perkin Trans. 2 1971, 1021-1029.
27. Schwyzer, R. Conformations and Orientations of Amphiphilic Peptides Induced by Artificial Lipid Membranes: Correlations with Biological Activity. Biochem. Mol. Biol. 1992, 3, 347-379.
28. 10]Dynorphin A-(1-11) Are Highly Selective for κ-Opioid Receptors. J. Med. Chem. 1992, 35, 4638-4639.
29. 2. J. Med. Chem. 1996, 39, 1136-1141.
30. Kieffer, B. L.; Befort, K.; Gaveriaux-Ruff, C.; Hirth, C. G. The δ-Opioid Receptor: Isolation of a cDNA by Expression Cloning and Pharmacological Characterization. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 12048-12052.
31. Bunzow, J. R.; Zhang, G.; Bouvier, C.; Saez, C.; Ronnekleiv, O. K.; Kelly, M. J.; Grandy, D. K. Characterization and Distribution of a Cloned Rat μ-Opioid Receptor. J. Neurochem. 1995, 64, 14-24.
32. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
33. Arunlakshana, O.; Schild, H. O. Some Quantitative Uses of Drug Antagonists. Br. J. Pharmacol. Chemother. 1959, 14, 48-58.